Top Smart Score Stocks
Analysts' Top Stocks
Insiders' Hot Stocks
Daily Stock Ratings
Daily Insider Transactions
Electronic Vehicles Stocks
Coronavirus Vaccine Stocks
High Dividend Stocks
My Portfolio Analysis
Profile & Performance
My Public Profile
Find & Follow Experts
Top 25 Wall Street Analysts
Top 25 Financial Bloggers
Top 25 Corporate Insiders
Top 25 Hedge Fund Managers
Top Individual Investors
Ideas & Insights
Calendars & Events
Stock Market Holidays
Become an Affiliate
Plans & Pricing
Amarin: Could the New CEO Help Vazkepa’s European Push?
There’s a big change in Amarin’s (AMRN) C-Suite and it looks like the Street is not happy about...
Apr 13, 2021
Amarin Pops 23% on Encouraging Late-Stage Vascepa Data from China Trial
Shares of Amarin surged 23% in after-hours trading on Thursday after it reported favorable and statistically significant top-line...
Nov 20, 2020
Good Entry Point for Amarin Stock? Not Just Yet, Says Analyst
Many companies will be glad to put 2020 behind them and you can certainly add Amarin (AMRN) to...
Nov 09, 2020
Amarin Pops 4% After-Hours On Positive PCI Data For Vascepa
Shares in Amarin (AMRN) popped 4% in Thursday’s after hours trading after the company presented encouraging data on...
Oct 16, 2020
Amarin Stock at $12 a Share? This Analyst Thinks It’s Possible
If you are looking for another successful biotech story in 2020, then look away now. Shares of Amarin...
Sep 29, 2020
Amarin (AMRN): Vascepa’s International Opportunity Remains Intact, Says Analyst
The markets might be in turmoil, but spare a thought for the current woes at biotech Amarin (AMRN)....
Sep 12, 2020
Amarin (AMRN) Bears the Brunt of a Price Target Cut
The appeal hearing for Amarin’s (AMRN) high triglyceride treatment Vascepa kicked off on Wednesday and ended on a...
Sep 03, 2020
Can Amarin Win Its Vascepa Appeal Case? Analyst Weighs In
It is gearing up to be a big week for Amarin (AMRN), as it awaits the opening of...
Sep 01, 2020
Amarin’s Vascepa To Take Part In Covid-19 Study In Adults With Heart Disease
Amarin announced on Friday that Kaiser Permanente Northern California (KPNC) is initiating a trial to study the potential of...
Aug 09, 2020
Amarin: Improving HCP Access Should Drive More Vascepa Sales, Says Analyst
Keeping it simple, biotech Amarin (AMRN) has one product. This means the company can focus solely on the...
Aug 06, 2020
Amarin (AMRN) Stock Will Likely Stay Range-Bound Near-Term, Says Analyst
2020 may have witnessed skyrocketing rallies for some biotechs, but it most certainly hasn’t been kind to Amarin...
Jun 18, 2020
Can Amarin Soar 420% Over the Next Year? This Analyst Thinks So
Amarin (AMRN) is seriously undervalued, according to Cantor analyst Louise Chen. On Monday, the drug maker presented encouraging...
Jun 17, 2020
Amarin, Apotex Settle Vascepa Dispute; Analyst Stays Sidelined
Amarin (AMRN) has announced a settlement agreement with Apotex Inc. that resolves a patent litigation over Apotex’s abbreviated...
Jun 17, 2020
Too Much Uncertainty Keeps This 5-Star Analyst Watching Amarin Stock From the Sidelines
Rewind to the end of 2019, and in the dead of winter, the sun appeared to be shining...
Jun 04, 2020
Will Courts Reverse Earlier Ruling on Amarin Patents? Analyst Weights In
It has been a rough couple of months for pharma company Amarin Corporation (AMRN). At the end of...
May 28, 2020
Amarin Down 10% in Pre-Market On Generic Approval
Shares in Amarin (AMRN) are plunging 10% in Friday’s pre-market trading on the news that Hikma Pharmaceuticals (HKMPY)...
May 22, 2020
Can Amarin (AMRN) Overcome Its Patent Headwinds? 5-Star Analyst Weighs In
The Amarin (AMRN) vs the Generics drama has entered a new stage. For the uninitiated, a quick recap:...
May 15, 2020